CD45RA + ICAM-3 + lymphocytes in interferon-β1b-treated and -untreated patients with relapsing-remitting multiple sclerosis

Acta Neurologica Scandinavica

Volumn 110, Issue 6, 2004, Pages 377-385

  Chatzimanolis, N ^a   Kraus, J ^a,b,f   Bauer, R ^a   Engelhardt, B ^b,c   Bregenzer, T ^d   Kuehne, B S ^a   Tofighi, J ^a   Laske, C ^a   Stolz, E ^a   Blaes, F ^a   Voigt, K ^a   Traupe, H ^e   Kaps, M ^a   Oschmann, P ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^d PAREXEL INTERNATIONAL   (United States)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Adhesion molecules; CD45RA; Flow cytometry; Interferon ; Lymphocyte subsets; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CD45 ANTIGEN; DICLOFENAC; INTERCELLULAR ADHESION MOLECULE 3; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN CD45RA; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; REMISSION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIGENS, CD; ANTIGENS, CD45; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; LYMPHOCYTE SUBSETS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS; RECURRENCE;

EID: 8844263007     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2004.00346.x     Document Type: Article

References (36)

1. NOSEWORTHY JH, LUCCHINETTI C, RODRIGUEZ M, WEINSHENKER BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. MARKOVIC-PLESE S, MCFARLAND HF. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 2001;1:257-62.
3. STEEN BJ, BREIER G, BUTCHER EC, SCHULZ M, ENGELHARDT B. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. Am J Pathol 1996;148:1819-38.
4. THE IFNB MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
5. PATY DW, LI DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7.
6. OZENCI V, KOUWENHOVEN M, HUANG YM, KIVISAKK P, LINK H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000;120:147-53.
7. LASKE C, OSCHMANN P, TOFIGHI J et al. Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Acta Neurol Scand 2001;103:105-13.
8. ARNASON BG. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996;81:1-11.
9. KRAUS J, LING AK, HAMM S, VOIGT K, OSCHMANN P, ENGELHARDT B. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann. Neurol 2004;56:192-205.
10. STONE LA, FRANK JA, ALBERT PS et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing remitting multiple sclerosis. Ann Neurol 1995;37:611-9.
11. DE FOUGEROLLES AR, SPRINGER TA. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med 1992;175:185-90.
12. ACEVEDO A, DEL POZO MA, ARROYO AG, SANCHEZ-MATEOS P, GONZALEZ-AMARO R, SANCHEZ-MADRID F. Distribution of ICAM-3-bearing cells in normal human tissues. Expression of a novel counter-receptor for LFA-1 in epidermal Langerhans cells. Am J Pathol 1993;143:774-83.
13. FAWCETT J, HOLNESS CL, NEEDHAM LA et al. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 1992;360:481-4.
14. ALTIN JG, SLOAN EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol 1997;75:430-45.
15. PARKIN J, COHEN B. An overview of the immune system. Lancet 2001;357:1777-89.
16. KRAUS J, OSCHMANN P, ENGELHARDT B et al. CD45RA + ICAM-3 + lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis. Acta Neurol Scand 2000;102:326-32.
17. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
18. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
19. KRAUS J, OSCHMANN P, ENGELHARDT B et al. Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity. Acta Neurol Scand 2000;101:135-9.
20. KRAUS J, ENGELHARDT B, CHATZIMANOLIS N et al. Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J Neuroimmunol 2002;122:175-85.
21. KRAUS J, KUEHNE BS, TOFIGHI J et al. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. Acta Neurol Scand 2002;105:300-8.
22. BANSIL S, TROIANO R, COOK SD, ROHOWSKY-KOCHAN C. Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. Acta Neurol Scand 1991;84:282-5.
23. GALLO P, PICCINNO MG, TAVOLATO B, SIDEN A. A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum. J Neurol Sci 1991;101:227-32.
24. Lu CZ, FREDRIKSON S, XIAO BG, LINK H. Interleukin-2 secreting cells in multiple sclerosis and controls. J Neurol Sci 1993;120:99-106.
25. LEPPERT D, WAUBANT E, BURK MR, OKSENBERG JR, HAUSER SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-52.
26. NORONHA A, TOSCAS A, JENSEN MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-53.
27. SALMAGGI A, CORSINI E, LA MANTIA L et al. Immunological monitoring of azathioprine treatment in multiple sclerosis patients. J Neurol 1997;244:167-74.
28. DE PAOLI P, BATTISTIN S, SANTINI GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol 1988;48:290-6.
29. MARTINO G, HARTUNG HP. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol 1999;12:309-21.
30. CALABRESI PA, TRANQUILL LR, DAMBROSIA JM et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-74.
31. CALABRESI PA, PELFREY CM, TRANQUILL LR, MALONI H, MCFARLAND HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997;49:1111-6.
32. CALOPA M, BAS J, MESTRE M, ARBIZU T, PERES J, BUENDIA E. T cell subsets in multiple sclerosis: a serial study. Acta Neurol Scand 1995;92:361-8.
33. CORSINI E, GELATI M, DUFOUR A et al. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J Neuroimmunol 1997;79:76-83.
34. GELATI M, CORSINI E, DUFOUR A et al. Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up. J Neurol 1999;246:569-73.
35. MATUSEVICIUS D, KIVISAKK P, NAVIKAS VV et al. Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. Eur J Neurol 1998;5:265-75.
36. OSSEGE LM, SINDERN E, PATZOLD T, MALIN JP. Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II. J Neuroimmunol 1998;91:73-81.